223 related articles for article (PubMed ID: 7651740)
1. Specific DNA binding by different classes of human p53 mutants.
Rolley N; Butcher S; Milner J
Oncogene; 1995 Aug; 11(4):763-70. PubMed ID: 7651740
[TBL] [Abstract][Full Text] [Related]
2. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro.
Hainaut P; Milner J
Cancer Res; 1993 Oct; 53(19):4469-73. PubMed ID: 8402615
[TBL] [Abstract][Full Text] [Related]
3. In vitro analysis of the dominant negative effect of p53 mutants.
Chène P
J Mol Biol; 1998 Aug; 281(2):205-9. PubMed ID: 9698540
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
5. A cellular protein activates the sequence-specific DNA-binding of p53 by interacting with the central conserved region.
Srinivasan R; Maxwell SA
Oncogene; 1996 Jan; 12(1):193-200. PubMed ID: 8552392
[TBL] [Abstract][Full Text] [Related]
6. The N terminus of the murine p53 tumour suppressor is an independent regulatory domain affecting activation and thermostability.
Hansen S; Lane DP; Midgley CA
J Mol Biol; 1998 Jan; 275(4):575-88. PubMed ID: 9466932
[TBL] [Abstract][Full Text] [Related]
7. Specific binding of MAR/SAR DNA-elements by mutant p53.
Müller BF; Paulsen D; Deppert W
Oncogene; 1996 May; 12(9):1941-52. PubMed ID: 8649855
[TBL] [Abstract][Full Text] [Related]
8. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence.
Niewolik D; Vojtesek B; Kovarik J
Oncogene; 1995 Mar; 10(5):881-90. PubMed ID: 7898929
[TBL] [Abstract][Full Text] [Related]
9. Novel DNA binding of p53 mutants and their role in transcriptional activation.
Zhang W; Funk WD; Wright WE; Shay JW; Deisseroth AB
Oncogene; 1993 Sep; 8(9):2555-9. PubMed ID: 8361764
[TBL] [Abstract][Full Text] [Related]
10. Restoration of the transcription activation function to mutant p53 in human cancer cells.
Abarzúa P; LoSardo JE; Gubler ML; Spathis R; Lu YA; Felix A; Neri A
Oncogene; 1996 Dec; 13(11):2477-82. PubMed ID: 8957091
[TBL] [Abstract][Full Text] [Related]
11. The DNA binding activity of wild type p53 is modulated by blocking its various antigenic epitopes.
Wolkowicz R; Elkind NB; Ronen D; Rotter V
Oncogene; 1995 Mar; 10(6):1167-74. PubMed ID: 7535417
[TBL] [Abstract][Full Text] [Related]
12. Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein.
Vojtesek B; Dolezalova H; Lauerova L; Svitakova M; Havlis P; Kovarik J; Midgley CA; Lane DP
Oncogene; 1995 Jan; 10(2):389-93. PubMed ID: 7530828
[TBL] [Abstract][Full Text] [Related]
13. New insights into p53 function from structural studies.
Arrowsmith CH; Morin P
Oncogene; 1996 Apr; 12(7):1379-85. PubMed ID: 8622853
[TBL] [Abstract][Full Text] [Related]
14. Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights.
Merabet A; Houlleberghs H; Maclagan K; Akanho E; Bui TT; Pagano B; Drake AF; Fraternali F; Nikolova PV
Biochem J; 2010 Mar; 427(2):225-36. PubMed ID: 20113312
[TBL] [Abstract][Full Text] [Related]
15. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
[TBL] [Abstract][Full Text] [Related]
16. [Relevance of p53 protein and its mutations for novel strategies in cancer therapy].
Müller P; Nenutil R; Vojtĕsek B
Cas Lek Cesk; 2004; 143(5):313-7. PubMed ID: 15305766
[TBL] [Abstract][Full Text] [Related]
17. Proteolytic cleavage of p53 mutants in response to mismatched DNA.
Mee T; Okorokov AL; Metcalfe S; Milner J
Br J Cancer; 1999 Sep; 81(2):212-8. PubMed ID: 10496344
[TBL] [Abstract][Full Text] [Related]
18. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53.
Abarzúa P; LoSardo JE; Gubler ML; Neri A
Cancer Res; 1995 Aug; 55(16):3490-4. PubMed ID: 7627952
[TBL] [Abstract][Full Text] [Related]
19. Activation of p53 DNA binding activity by point mutation.
Marston NJ; Ludwig RL; Vousden KH
Oncogene; 1998 Jun; 16(24):3123-31. PubMed ID: 9671391
[TBL] [Abstract][Full Text] [Related]
20. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
Di Como CJ; Prives C
Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
